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Abstract Cancer and its treatment can lead in men to
testosterone deficiency, accompanied by somatic and
mental symptoms. Germ cell tumours and their treatment
may disturb the pituitary–gonadal axis, hence leading to
significant clinical abnormalities. In some prostate cancer
patients, castration, temporary or permanent, is a desired
therapeutic condition. Yet, it is burdened with various side
effects of complex intensity and significance. Last but not
least, patients in the terminal stage of a malignancy present
with low testosterone concentrations as a part of anorexia–
cachexia syndrome. Oncological management of such
patients disturbs their homeostasis, androgen metabolism
included, which results in numerous complications and
worsens their quality of life. In the present paper, we
analysed the frequency and sequelae of testosterone defi-
ciency in some clinical scenarios, on the basis of original
papers, meta-analyses and reviews available in PubMed.
Androgen secretion disorders in male cancer patients
depend on a cancer type, stage and methods of treatment.
Number of testicular cancer survivors is increasing, and as
a consequence, more patients cope with late complications,
testosterone deficiency included. Hormone therapy in
prostate cancer patients significantly prolongs survival, and
then numerous men experience long-term adverse effects
of androgen deficiency. Those, in turn, particularly the
metabolic syndrome, may contribute to increased mortal-
ity. Androgen deficiency is a part of cancer anorexia–
cachexia syndrome. The role of androgen deficiency in
cancer patients is still under debate, and further studies are
urgently needed to establish appropriate clinical guidelines.
Keywords Testosterone  Hypogonadism  Testicular
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Introduction
Hypogonadism in men is defined as clinical symptoms
resulting from androgen deficiency [1, 2]. Diagnosis of
testosterone deficiency remains a challenge. Various ref-
erence values are presented in the literature data. It is
agreed that testosterone deficiency is unequivocal in case
of total serum testosterone below 8 nmol/L. In such cases,
hormone replacement therapy is recommended unless
contraindicated. Total testosterone concentration of
8–12 nmol/L accompanied by clinical symptoms of
testosterone deficiency is a rationale for commencing test
supplementation [3]. Threshold values in different units of
testosterone concentration are presented in Fig. 1.
The frequency of androgen deficiency increases with
age; the postulated testosterone decrease in adult men is
0.4–2.0% per annum [4].
Testosterone exerts an endocrine effect on target organs
but also has paracrine and autocrine effects on testicular
tissue, hence regulating spermatogenesis [5]. Impaired
androgen activity in postpubertal men may lead to infer-
tility, sexual disorders, muscular weakness, increased fatty
tissue mass, bone demineralisation, metabolic disorders
and haematopoiesis impairment [6, 7]. Physiological
testosterone concentrations have a beneficial effect on
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metabolism, and low testosterone can be linked with
metabolic syndrome [8]. Diagnostic criteria of metabolic
syndrome are presented in Table 1 [9].
Hormonal receptors of the hypothalamus–pituitary–go-
nadal axis can be identified in various areas of the male
brain. Sex hormones affect numerous cerebral structures,
especially the hippocampus, amygdaloid body and the
prefrontal cortex [10, 11]. As a result, apart from obvious
changes in sexual behaviour, androgen deficiency leads to a
higher anxiety level, prevalence of depression and impaired
cognitive functions.
In summary, normal androgen concentrations are crucial
for men’s well-being. Health, according to the World
Health Organisation, is a state of ‘physical, mental and
social well-being, not merely the absence of disease or
infirmity’.
Materials and methods
In this paper, we analysed articles published in PubMed,
using the following keywords: ‘low testosterone level’,
‘hypogonadism’, ‘testicular germ cell tumour’, ‘prostate
cancer’, ‘androgen deprivation therapy (ADT)’, ‘side
effects’, ‘metastatic cancer’, ‘cachexia’ and ‘testosterone’.
In addition, we analysed the guidelines published by
American Association of Clinical Endocrinologists
(AACE), European Association of Urology (EAU) and
Fig. 1 Threshold values in different units of testosterone concentration
Table 1 Diagnostic criteria for metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-
ATP III), 2001, International Diabetes Federation (IDF) and JIS—collaborative definition of IDF, AHA, NHLBI, WHF and IAS, 2009
NCEP-ATP III IDF JIS
Arterial hypertension Systolic BP C 130 mmHg
Diastolic BP C 85 mmHg or treated
hypertension
Systolic BP C 130 mmHg
Diastolic BP C 85 mmHg or treated
hypertension
Systolic BP C 130 mmHg
Diastolic BP C 85 mmHg or treated
hypertension
Obesity Waist circumference C88 cm in
women and C102 cm in men
Waist circumference C80 cm in
women and C94 cm in men or BMI
[30 kg/m2
Waist circumference C80 cm in
women and C94 cm in men
Insulin resistance Fasting plasma glucose C6.1 mmol/l
(110 mg/dl)
Fasting plasma glucose C5.6 mmol/l
(100 mg/dl)
Fasting plasma glucose C5.6 mmol/l
(100 mg/dl) or pharmacological
treatment of type II diabetes mellitus
Dyslipidaemia HDL-C\ 1.03 mmol/L (40 mg/dl) in
men and\1.3 mmol/l (50 mg/dl) in
women or treatment with statins
HDL-C\ 1.03 mmol/L (40 mg/dl) in
men and\1.3 mmol/l (50 mg/dl) in
women or treatment with statins
HDL-C\ 1.03 mmol/L (40 mg/dl) in
men and\1.3 mmol/l (50 mg/dl) in
women or dyslipidaemia treatment
Hypertriglyceridemia Triglycerides[1.7 mmol/l (150 mg/
dl) or hypertriglyceridemia
treatment
Triglycerides[1.7 mmol/l (150 mg/
dl) or hypertriglyceridemia
treatment
Triglycerides[1.7 mmol/l (150 mg/
dl) or hypertriglyceridemia treatment
Metabolic syndrome C3 criteria Obesity and C2 other criteria C3 criteria
NCEP-ATP III National Cholesterol Education Program Adult Treatment Panel III, 2001, IDF International Diabetes Federation, JIS metabolic
syndrome definition according to consensus of IDF, NHLB Institute National Heart, Lung and Blood Institute, AHA American Heart Association,
WHF World Heart Federation, IAS International Atherosclerosis Society and IAS Obesity, 2009, BP blood pressure, HDL-C High-Density
Lipoprotein Cholesterol
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European Society for Medical Oncology (ESMO) regard-
ing testosterone deficiency in cancer patients.
Testosterone deficiency in selected clinical
situations
Germ cell tumours
Germ cell tumours account for the majority of testicular
malignancies. The incidence peaks in the age group of
15–36 and is still rising [12]. In view of the excellent
outcomes, the interest shifts to late and chronic negative
sequelae of the disease and its treatment.
The risk of decreased testosterone concentration years
after successful treatment of germ cell tumours mounts
even to 25% [13–22]. Table 2 shows the risk of testos-
terone deficiency in this group of patients.
The total testosterone deficiency in men after unilateral
orchiectomy for germ cell tumours tends to attenuate over
time [13–22]. The concentrations return to normal limits as
soon as 2 years after treatment [15] and after 10 years do
not differ from those observed in the healthy population.
However, a more frequent finding is the so-called com-
pensated hypogonadism, i.e. elevated luteinising hormone
(LH) with normal testosterone levels; this can be observed
in 75% patients. The reported incidence of compensated
hypogonadism is presented in Table 3.
All authors report on the chronic nature of compensated
hypogonadism [13–20], diagnosed even 10 years after the
completion of treatment [14]. LH concentration is regarded
as a better indicator of hormonal changes many years after
unilateral orchiectomy [14, 16, 19, 20, 24, 25].
Lowering the testosterone/LH ratio may reflect the
decrease in testicular volume; however, the progressive
decrease in this ratio may be a sign of Leydig cell damage
[14, 26]. This, in turn, results from exposure to cisplatin,
the main cytotoxic agent used in germ cell tumours treat-
ment [16, 20]. Nevertheless, orchiectomy remains the
principal cause of this disorder [13]. The hormonal alter-
ations reflect the accelerated ageing of the pituitary–tes-
ticular axis.
Testicular cancer survivors often present with over-
weight, hypercholesterolaemia, arterial hypertension (24,
24 and 30%, respectively). 25% of patients fulfil the cri-
teria of metabolic syndrome. Testosterone concentration
below 15 nmol/l (22% patients) proved to be associated
with a higher risk of metabolic syndrome (OR 4.1, 95% CI
1.8–9.3) [27]. Relative risk (HR) of metabolic syndrome in
testicular cancer survivors in comparison with the healthy
population was 1.9, or even higher in patient receiving
chemotherapy (HR 2.2 according to NCEP-ATP criteria
and 2.3—IDF criteria). Similarly, a highest risk was seen in
patients within the lowest testosterone quartile (HR 2.5)
[28]. Particularly concerning is the 3.1-fold increase in the
risk of myocardial infarction. The risk of cardiovascular
complications is clearly related to methods of post-
orchiectomy treatment, i.e. chemo- and radiotherapy
[28, 29].
In germ cell tumour patients, a negative impact of
hypogonadism on the quality of life after unilateral
orchiectomy was confirmed by Huddart [23]. Disorders of
the pituitary–testicular axis negatively affect physical well-
being, sexual functions and mood [20]. However, other
authors do not confirm the effect of testosterone deficiency
on mood and anxiety levels [30]. The sole decrease in
Table 2 Testosterone deficiency in testicular cancer patients after completion of treatment
Study Number of
patients (n)
Threshold for testosterone
(T) concentration (LLN)
Median T concentration
after the treatment
Percentage of patients with
testosterone deficiency (%)
Pühse et al. [13] 160 9.85 nmol/L NA 11–33
Nord et al. [14] 1183 8 nmol/L 16.7 (14.8–18.7) nmol/L NA
Eberhard et al. [15] 143 10 nmol/L 13 (3–22) nmol/L NA
Berger et al. [16] 63 3 ng/mL 5 (1.5–11.1) ng/ml 17
Gerl et al.a [17] 117 10 nmol/L 16.3 (6.0–55.7) nmol/L 11
Lackner et al. [18] 83 3 ng/mL NA 25.3
Ondrusova et al. [19] 823 12 nmol/L NA 15.1
Wiechno et al. [20] 326 2.6 ng/mL 0.2–11.8 ng/mL 15
O’Carrigan et al. [21] 54 8 nmol/L 13 nmol/L 13
Willemse et al.b [22] 176b 8 nmol/L 6.4–32.1 nmol/L 17.6
T testosterone, LLN lower limit of normal, NA not available
a Patients undergoing surgery with subsequent chemotherapy, with cumulative cisplatin dose of max. 400 mg/m2, median values
b Patients undergoing combination chemotherapy, hypogonadism defined as T\ 10 nmol/L
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testosterone concentration after unilateral orchiectomy
does not necessarily worsen sexual functions [18, 20].
Since impaired androgen metabolism may negatively
affect somatic and mental status of testicular cancer sur-
vivors, the question of testosterone supplementation arises.
Recovering physiological testosterone concentrations
increases the muscular mass and strength, increases bone
mineralisation and the lean body mass, decreases the waist
circumference and insulin resistance as well as improves
lipid metabolism [31–35]. Testosterone supplementation
improves sexual functions in hypogonadic men [36] as well
as alleviates depression and cognitive disorders [37, 38].
However, there is a lack of studies assessing effects of
testosterone supplementation after unilateral orchiectomy.
It is unclear when androgen supplementation should be
commenced or whether it should be maintained for decades
of the survivors’ lives, especially in view of the tendency
of testosterone deficiency to attenuate over time.
Prostate cancer
Prostate cancer is a classic example of an androgen-de-
pendent malignancy. Metastatic and symptomatic disease
is a typical indication for castration, surgical or pharma-
cological. Disseminated prostate cancer requires continu-
ous androgen ablation [39, 40]. Long life expectancy in this
group ensures a long-term therapeutic benefit but at the
cost of adverse effects. In patients qualified for radical
radiotherapy, hormone therapy must be added as adjuvant
treatment in high-risk patients (for 2–3 years) and may be
considered in intermediate-risk patients (for 6 months)
[39, 40].
The risk of metabolic syndrome in prostate cancer
patients undergoing hormone therapy exceeds 50% and is
significantly higher in comparison with the control group
[41, 42]. The frequency of metabolic syndrome in prostate
cancer patients not receiving hormone therapy is 22%,
whereas in androgen-deprived patients is as high as 55%
[41]. Prostate cancer patients also present with higher
serum glucose concentrations in comparison with the
control group [41]. In an analysis of 37,443 men with
prostate cancer undergoing treatment with LH-RH ana-
logues, the relative risk of diabetes was 1.44 [43]. A
decrease in testosterone concentration leads to an increase
in fasting insulin and low-density lipoproteins (LDL) as
early as 3 months after androgen deprivation therapy
(ADT) commencement. Moreover, serum glucose, total
cholesterol and high-density lipoproteins (HDL) increase
1 year later, accompanied by increasing waist circumfer-
ence [44] and triglycerides concentration [45]. According
to a meta-analysis, the relative risk of metabolic syndrome
and diabetes in men undergoing ADT is 1.75 and 1.36,
respectively [46]. ADT-driven abnormalities, in opposition
to the typical metabolic syndrome, include a tendency to
Table 3 Compensated hypogonadism in testicular cancer patients after completion of treatment
Study Number of
patients (n)
Threshold for testosterone
(T) concentration (LLN)
Threshold for LH
concentration (ULN)
Percentage of patients with overt
(T\LLN)/compensated hypogonadism
(T[LLN and LH[ULN)/total
Pühse et al. [13] 160 9.85 nmol/L 8.95 mU/mL NA/NA/NA
Nord et al.a [14] 373 8 nmol/L 12 IU/L NA/NA/19%
Eberhard et al.
[15]
143 10 nmol/L 10 IU/L NA/NA/37%
Berger et al. [16] 63 3 ng/mL 15 10%/24%/NA
Gerl et al.b [17] 117 10 nmol/L 8 IU/L 11%/19%/NA
Lackner et al. [18] 83 3 ng/mL 6.9 mU/mL NA/NA/26.5%
Ondrusova et al.
[19]
823 12 nmol/L 8.2 mIU/mL 15%/15.1%/NA
Wiechno et al.
[20]
326 2.6 ng/mL 6.1 mIU/mL 15%/55%/NA
O’Carrigan et al.
[21]
54 8 nmol/L NA 13%/NA/33%
Willemse et al.c
[22]
176b 8 nmol/L 10 IU/L NA/NA/17.6%
Huddart et al. [23] 272 10 ng/mL 12 IU/L 15%/13%/NA
T testosterone, LLN lower limit of normal, ULN upper limit of normal, NA not available
a Patients undergoing chemotherapy, with cumulative cisplatin dose of max. 850 mg/m2
b Patients undergoing surgery with subsequent chemotherapy, with cumulative cisplatin dose of max. 400 mg/m2, median values
c Patients undergoing combination chemotherapy, hypogonadism defined as T\ 10 nmol/L
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subcutaneous fat deposits and high-density lipoproteins
(HDL) increase [44, 47]. This syndrome is associated with
a 3-fold increase in cardiovascular diseases incidence [41]
as well as with type II diabetes.
The relationship between cardiovascular system and
ADT remains a matter of controversy. ADT leads to a
poorer control of arterial hypertension [48, 49], although
short-term treatment does not necessarily increase blood
pressure values [47]. A 20% increase in the risk of serious
cardiovascular diseases along with a significant increase in
fatal incidents (HR 2.6) has been reported [50]. The liter-
ature data also suggest an increased risk of myocardial
infarctions, sudden cardiac deaths and life-threatening
ventricular arrhythmias [43]. However, contradictory
reports also exist, suggesting a lack of association between
ADT and myocardial infarctions and sudden deaths [51] as
well as increased mortality due to cardiovascular condi-
tions [52–54]. A meta-analysis of 8 randomised trials did
not confirm a relation between either short-term ADT
(\6 months) or long-term ADT ([3 years) and an
increased risk of cardiovascular complications [55]. The
majority of prostate cancer patients have a history of
metabolic or cardiovascular disorders, or at least risk fac-
tors predisposing to diabetes or cardiovascular diseases,
present before the diagnosis of malignancy. In these
patients, ADT with gonadotropin-releasing hormone
(GnRH) antagonists is less likely to result in cardiovascular
incidents than GnRH agonists [56].
According to current guidelines, patients undergoing
ADT should be monitored for lipid disorders and glucose
intolerance. Consulting a cardiologist should be considered
in patients with the aforementioned comorbidities or aged
over 65 [40]. To prevent metabolic complications, a heal-
thy lifestyle (i.e. smoking cessation, maintaining a proper
body weight, physical activity) is advised. A meta-analysis
of trials assessing physical exercise revealed an improve-
ment in patients’ body constitution and quality of life [57].
When metabolic complications or cardiovascular disorders
occur, statins, hypoglycaemising agents, acetylsalicylic
acid or hypotensive medications are used. Metformin,
introduced gradually up to the dose of 850 mg twice daily
and combined with lifestyle factors, may ameliorate the
body constitution and cardiovascular status [58].
Maintaining castration in men leads to a progressive loss
of bone mass and this, in turn, to an increased risk of
pathological fractures [59]. Prior to ADT, only 19.4% men
present with normal bone density; risk of osteoporosis in
this group equals 35.4%. In the course of treatment, the
osteoporosis risk increases to 49.2% after 2 years and
further to 80.6% after 10 years [60]. Bone density moni-
toring, lifestyle modifications (i.e. physical exercise,
smoking cessation, weight reduction, avoiding alcohol
consumption) and supplementation of calcium (1500 mg
daily) and vitamin D (800 IU daily) are therefore recom-
mended. Zoledronic acid is capable of inhibiting bone loss
[61] and is labelled for use in patients with skeletal
metastases. Denosumab, administered at the dose of
120 mg every 4 weeks, proved more effective in prevent-
ing skeletal-related events (SRE) in patients with bone
metastases [62]. Moreover, on the basis of clinical trials,
denosumab has been approved for preventing bone loss in
men undergoing ADT (60 mg every 6 months) [63].
On ADT, haemoglobin concentration in men with non-
metastatic prostate cancer is gradually decreasing, usually
by 1–2 g/dL [64, 65]. In most cases, anaemia is mild and
does not worsen quality of life, hence not requiring an
intervention [66]. Significant anaemia usually implies
cancer progression or is associated with adverse effects of
treatment. Management of profound anaemia is a complex
problem, beyond the scope of this paper.
80% of ADT patients present with hot flushes; 27% of
these consider this symptom the most disturbing side
effect, which may continue even after ADT completion
[67, 68]. Hot flushes tend to be more pronounced in
younger men, with a lower body mass index (BMI). Their
intensity is affected by polymorphism in genes encoding
agents responsible for vasoconstriction, immunological
response, circadian rhythms and neurotransmission [69].
Management of hot flushes includes hormonal agents, e.g.
megestrol acetate, medroxyprogesterone acetate, diethyl-
stilbestrol and cyproterone acetate [70]. According to a
randomised clinical trial, venlafaxine is less effective than
hormonal medications [71]. Gabapentin administered at
bedtime has proved to reduce intensity of hot flushes and
night drenching sweats [72].
Prostate cancer patients undergoing ADT often report
growing fatigue (compared to patients without ADT), fur-
ther exacerbated by comorbidities [73, 74]. Fatigue, in turn,
may lead to depression [75, 76]. ADT adverse events are
associated with depression and anxiety [75, 76]. Cognitive
impairment as early as after 6 months of treatment has
been reported [76], although some authors did not confirm
these results [76, 77]. A meta-analysis of fourteen trials
only revealed deficits in visual-motor tasks [78]. ADT
increases the risk of depression by 23% as well as fre-
quency of hospitalisations and ambulatory psychiatric
consultations [79]. Sexual functions are disabled even after
a short-term adjuvant treatment [77, 80]. ADT leads to
decreased libido and sex activity as well as lowered sense
of masculinity which progresses up to 9 months of treat-
ment. Intermittent ADT may restore sexual activity in 52%
of patients who were active before the treatment [81].
Sexual disorders may result in relationship problems and
quality of life impairment. Therefore, patients scheduled
for ADT should be informed about potential adverse
effects and offered psychological support [82].
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Intermittent ADT was introduced to limit adverse effects
in palliative patients. According to the European Associa-
tion of Urology (EAU), intermittent ADT does not worsen
overall survival (OS); the treatment costs are lower and
adverse effects less frequent. This opinion is based on
results of a meta-analysis (2014) [83]. Contrarily, European
Society for Medical Oncology (ESMO) does not recom-
mend intermittent ADT in metastatic prostate cancer
patients as the trial designed to prove non-inferiority of
such approach to continuous ADT gave negative results
[84].
Hormone replacement therapy attenuates symptoms of
hypogonadism, hence improving the quality of life. Despite
historical controversies, such treatment may now be
regarded safe in patients without an active cancer, given
that recurrence risk is low [55].
Metastatic cancer and cachexia syndrome
According to the WHO data, the overall cancer mortality in
men in the world and in Europe is 7,410,000 and 716,000,
respectively. Hence, a significant number of patients are
bound to experience a terminal stage of their diseases [85].
Androgen disorders are observed in the majority of men
with a metastatic cancer [86] and even in 90% patients
treated with opioids for disease-related symptoms [87].
Their intensity is particularly high in patients with cachexia
syndrome [88]. The concentrations of bioavailable testos-
terone in men with advanced malignancies were proved
lower than in the control group; prostate cancer patients
were excluded from the analysis. Moreover, decreased
testosterone levels were associated with a significant
increase in LH concentration. Such results suggest testic-
ular insufficiency in the terminal stage of malignancies
[89].
Opioid administration is also related to androgen defi-
ciency [86, 87, 90], as their mode of action involves delta
receptors localised on GnRH-secreting neurons [91]. This,
in turn, inhibits the pituitary–gonadal axis, hence decreas-
ing the testosterone secretion [92].
Alkylating agents, platinum compounds included, also
impair the gonads and their secretory functions [93].
Additionally, high concentrations of inflammatory
cytokines (e.g. interleukin-6) observed in advanced
malignancies inhibit the pituitary–gonadal axis, hence
increasing androgen deficiency. Similar abnormalities may
be due to altered concentrations of polypeptides regulating
the energy homeostasis [89, 94].
Androgen deficiency also leads to appetite loss [89],
thus forming a vicious circle and exacerbating the cachexia
syndrome. Low concentrations of free testosterone are
associated with weight loss and shorter overall survival in
men with pancreatic cancer [90]. The relationship between
low testosterone concentrations and negative survival
prognosis has been confirmed by other authors [86]. Men
with advanced cancers and androgen deficiency present
with fatigue, anxiety, impaired well-being, a worse per-
formance status according to Eastern Cooperative Oncol-
ogy Group (ECOG), appetite loss and increased
inflammatory parameters [86, 88]. In summary, androgen
deficiency plays an important role in complex disorders
accounting for cancer cachexia syndrome. Nevertheless,
the data regarding testosterone supplementation in this
group are sparse. According to available literature, andro-
gens in the management of cachexia syndrome seem less
effective than either dexamethasone or megestrol acetate
[95, 96]. On the other hand, in a placebo-controlled ran-
domised clinical trial, androgen supplementation inhibited
inflammatory processes in hypogonadic men [97]. Since
inflammation contributes to cachexia syndrome, further
studies on androgen supplementation are warranted.
Conclusions
Androgen secretion disorders in male cancer patients
depend on a cancer type, stage and methods of treatment.
Germ cell tumours are managed with radical intent;
hence, the number of survivors is increasing. As a conse-
quence, more patients cope with late complications,
testosterone deficiency included. The principals of testos-
terone deficiency management are still to be established.
Hormone therapy in prostate cancer patients signifi-
cantly prolongs survival, which makes many of them
experience long-term adverse effects of androgen defi-
ciency. Those, in turn, particularly the metabolic syn-
drome, may contribute to increased mortality. Proper
prophylaxis and treatment of those adverse events should
be seen as a part of clinical practice.
Androgen deficiency is a part of cancer anorexia–
cachexia syndrome. The role of androgen supplementation
in this group of patients is still under debate.
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